CSIR allows Cipla to launch Favipiravir in India


The Council of Scientific and Industrial Research (CSIR) constituent lab CSIR-Indian Institute of Chemical Technology (CSIR-IICT) has developed a cost-effective process using locally available chemicals to synthesize an off-patent anti-viral drug Favipiravir and transferred the technology to leading pharmaceutical industry Cipla Limited.

Originally discovered by Fuji, Japan, the Favipiravir has shown promise in clinical trials for the treatment of Covid-19 patients, especially the mild and moderate patients.


Cipla has scaled up the process in their manufacturing facility and approached DCGI for permission to launch the product in India. Given that DCGI has given restricted emergency use for Favipiravir in the country, Cipla is now all set to launch the product to help patients suffering from Covid-19.

Commenting on the development, Director CSIR-IICR, Dr S Chandrashekhar said that the technology provided by CSIR-IICT is very efficient and makes it affordable and allows Cipla to make large quantities of the product within a short span of time.

DG-CSIR, Dr Shekhar C Mande observed that CSIR is working with industry in developing quick solutions and products for mitigation of Covid-19 and this partnership with Cipla is an example of how CSIR is committed to bringing repurposed drugs on a fast track.